Pharmidex - Empowering CNS drug discovery


	>pharmidex		>insights >into CNS drug discovery

New Page 1

	CLINICAL CANDIDATE PROFILING IntegrityPLUS™ is the same as Integrity™ but with more comprehensive assessment of efficacy and side-effect liability and the possibility of conducing studies to a GLP standard. It permits assessment of: > Brain exposure (NeuroPK®) > DMPK profile, including bioavailability > Therapeutic efficacy > Side-effect liability Compared to Integrity™, both the dosing regimens and the assessment of the consequences of compound administration will be more extensive

	IntegrityPLUS™ provides an important test of whether a compound is safe and effective, prior to administration to humans. The NeuroPK® component ensures that the dosing regimen in humans is on the basis of the concentration profile in brain interstitial fluid – and not blood PK alone. Together, these measures provide comprehensive and rigorous testing prior to administration to humans, which increases the probability of success in subsequent clinical trials.



	Pharmidex adds value at each level of the R&D process
	Pharmidex provides a clear corporate advantage at every level the R & D process’ Value is added to a particular project on the basis of: a. Increased certainty of success b. Decreased time to market For more information click here

Pharmidex adds value at each level of the R&D process